-
公开(公告)号：US11634488B2
公开(公告)日：2023-04-25
申请号：US16630351
申请日：2018-07-10
Applicant: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH
Inventor： Claudine Vermot-Desroches , Chanthy Kong-Flohr , Marc Godinat , Bruno Cavallini
Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
-
公开(公告)号：USRE49192E1
公开(公告)日：2022-08-30
申请号：US16427106
申请日：2019-05-30
Applicant: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH
Inventor： Claudine Vermot-Desroches , Boris Sebastien Vuillermoz
Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
-
公开(公告)号：US12077597B2
公开(公告)日：2024-09-03
申请号：US17534707
申请日：2021-11-24
Applicant: INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH
Inventor： Claudine Vermot-Desroches , Hélène Rouquette , Benoît Milcent
CPC classification number: C07K16/2896 , A61P35/00 , A61P35/02 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/734
Abstract: Novels antibodies, preferably monoclonal antibodies, or antigen-binding fragments thereof, said antibody or fragment thereof specifically binding to CD5. These antibodies may be used as a medicament, especially in the treatment of diseases in immunomodulation, inflammation, virology, infectiology, autoimmunity and oncology domains. Immune cells and/or cancer cells targeted by the invention are expressing CD5 antigen. These antibodies may be in particular chimeric or humanized. The invention also relates to pharmaceutical compositions, such as immunomodulator, anti-cancerous and anti-infectious compositions, containing such an antibody or antigen-binding fragment and methods of use of these, either for laboratory work, in drug manufacturing, such as in cell therapy cells production, or for medical treatment.
-
公开(公告)号：US10533046B2
公开(公告)日：2020-01-14
申请号：US15502469
申请日：2015-08-10
Applicant: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH , UNIVERSITE CLAUDE BERNARD LYON 1 , HOSPICES CIVILS DE LYON , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE LEON BERARD
Inventor： Marie Alexandra Albaret , Jean-Jacques Diaz , Hichem Claude Mertani , Jean-Christophe Saurin , Claudine Vermot-Desroches , Boris Vuillermoz
IPC: C07K16/18 , C07K16/30 , A61P35/00 , A61K39/395 , C07K7/06 , A61K39/00 , A61K45/06 , G01N33/574
Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.
-
-
-
Search Results
4
records
(took 0.013 seconds)
